EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

The Chronic Headache Self‐Efficacy Scale: Development and assessment of measurement properties

Lori M Ginoza, Erica Sigman, Lori A Michener, Rachel K Straub, Soma Sahai-Srivastava, Federico Pozzi iD

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14888 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Lori M Ginoza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Self Efficacy, Psychometrics, Headache Disorders. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Science (NCATS) of the U.S. National Institutes of Health, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To develop and assess the psychometrics of the Chronic Headache Self‐Efficacy Scale (CHASE).

Background

Existing scales assess self‐efficacy in coping strategies and management of symptoms and triggers but do not measure other important self‐efficacy domains, such as performing daily activities and socializing in patients with chronic daily headache (CDH).

Methods

The study had two phases: (i) Development of the 14‐item CHASE, with items derived from patients with CDH and a multidisciplinary healthcare team; (ii) longitudinal observational study for psychometric evaluation. Participants with CDH ( N = 79) completed the CHASE, Headache Management Self‐Efficacy Scale (HMSE), six‐item Headache Impact Test‐6 (HIT‐6), and 12‐item Short Form Health Survey (SF‐12) at baseline, 24–72 h after baseline, and 12 weeks after baseline. The Global Rating of Change (GROC) assessed perceived change in symptoms. We assessed internal consistency, day‐to‐day reliability, convergent and known group discriminant validity, dimensionality, and responsiveness via minimal clinical important difference (MCID).

Results

For day‐to‐day reliability, the CHASE intraclass correlation coefficient was 0.68 (95% confidence interval 0.49–0.81), with standard error of measurement and minimal detectable change of 10.3% and 24%, respectively. The CHASE had two independent factors (total R 2 = 54.5%) that can be combined into a single score (Cronbach's alpha internal consistency 0.88). For convergent validity, the CHASE score was related to the HIT‐6, HMSE, and SF‐12 ( R 2 : 0.17–0.29, all p < 0.001). For known group discriminant validity, individuals with an active headache had a lower CHASE score than those without (mean [standard deviation] 47.7 [17.3]% vs. 57.2 [19.8]%, p < 0.001). Classification and regression tree analysis showed the MCID for meaningful positive symptom change on the GROC was a CHASE change of >8% or CHASE change of 8% with baseline CHASE >67%.

Conclusion

The CHASE is a reliable and valid questionnaire for assessing self‐efficacy in performing daily activities, socializing, managing headache symptoms and triggers, and guiding treatment plans for patients with CDH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Self EfficacyPsychometricsHeadache DisordersHumansMaleFemaleAdultMiddle AgedReproducibility of ResultsLongitudinal StudiesYoung AdultAgedSurveys and Questionnaires

Stichwörter der Autor:innen

chronic daily headachemigrainepatient‐reported outcomepsychometric analysisreliabilityvalidity

Autor:innen und Institutionen

  • Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, California, USA.
  • Department of Neurology, University of Southern California, Los Angeles, California, USA.
  • Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Federico Pozzi

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Science (NCATS) of the U.S. National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Ginoza, L. M., Sigman, E., Michener, L. A., Straub, R. K., Sahai-Srivastava, S., & Pozzi, F. (2025). The Chronic Headache Self‐Efficacy Scale: Development and assessment of measurement properties. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14888

Vancouver

Ginoza LM, Sigman E, Michener LA, Straub RK, Sahai-Srivastava S, Pozzi F. The Chronic Headache Self‐Efficacy Scale: Development and assessment of measurement properties. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14888

BibTeX
@article{Ginoza2025,
  author = {Ginoza, Lori M and Sigman, Erica and Michener, Lori A and Straub, Rachel K and Sahai-Srivastava, Soma and Pozzi, Federico},
  title = {The Chronic Headache Self‐Efficacy Scale: Development and assessment of measurement properties},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14888}
}
Kostenlos starten →